The trial into the now-defunct blood testing startup Theranos has begun, with founder Elizabeth Holmes facing several charges of criminal fraud.
Prosecutors alleged Holmes “lied and cheated” for money and fame during the first day of one of the most closely watched trials of a U.S corporate executive in years.
The former Silicon Valley star is accused of deceiving investors and patients, by claiming Theranos technology could detect common illnesses using just a few drops of blood from a finger prick.
The company collapsed in 2015 after it emerged the blood-testing devices did not work, and had instead been operating commercially available machines made by other manufacturers.
“Significant problems brewing”
Prosecutors claimed that Holmes and other executives turned to fraud in 2009 after big pharmaceutical firms refused to back Theranos and the company faced bankruptcy.
Holmes lied about tests and exaggerated the company’s performance to secure millions of dollars of investments between 2010 to 2015.
This included false claims that the tests had been processed by pharmaceutical giant Pfizer, and that the technology was being used in the field by the U.S military.
Defence tells court Holmes is “no villain”
At the centre of Holmes’ defence is the argument she never intended to commit fraud.
Instead, they argue, Theranos is a high-profile example of a startup that simply did not work, much like thousands of other failed business ideas.
They told jurors that Holmes is not a villain, but rather a hard-working, young and naive businesswoman, who poured much of her life into the company.
“Failure is not a crime. Trying your hardest and coming up short is not a crime,” defence attorney Lance Wade said.
“In the end, Theranos failed and Ms Holmes walked away with nothing,” he told the jury.
Former executive and romantic partner also charged
Ex-Theranos executive Ramesh Balwani – who was romantically involved with Holmes for years, faces the same charges, but will be tried separately.
He has pleaded not guilty.
According to court documents released to the public, Holmes has accused Balwani of years of emotional and psychological abuse – allegations which Balwani denies.
Holmes’ lawyers have indicated she is highly likely to take the witness stand and testify about the effect her relationship with Balwani had on her mental state.
Court case the culmination of ill-fated saga
Holmes’ story is one which has peaked public interest.
After founding Theranos in 2003, aged 19, Holmes was fast-tracked for Silicon Valley success – she was at one point dubbed the world’s youngest self-made female billionaire and the “next Steve Jobs”.
Theranos “dazzled” large firms such as Walgreens and pharmacy companies into agreeing testing partnerships, as well as securing investments from high-profile figures like media mogul Rupert Murdoch and former U.S secretary of state Henry Kissinger.
Her story has become the subject of documentaries, podcasts and books. A TV miniseries and a film based on her life are in the works.
A tumultuous story will now culminate in a decision made in a California courtroom, with the case expected to last months.
ASX200 rises amid potential US rate cuts and Chinese stimulus as mining and banks drive market gains.
In Short
The Australian share market rose, driven by hopes for a US interest rate cut and potential Chinese stimulus, with significant gains in resources and energy sectors. The ASX200 closed up 64.4 points, while some tech stocks had mixed results and Clarity Pharmaceuticals was the biggest loser.
The Australian share market experienced a significant uplift today, driven largely by discussions surrounding a potential interest rate cut by the US Federal Reserve and the anticipated stimulus measures from China.
The ASX200 rose by 64.4 points, or 0.83 per cent, closing at 7854.1. The All Ordinaries index also saw gains of 68.80 points, or 0.86 per cent, ending at 8082.1.
The Australian dollar appreciated by 0.03 per cent, purchasing US63.25 cents at the market close.
Eight of the eleven sectors in the ASX concluded positively, with the materials sector leading the way, increasing by 1.58 per cent.
Speculation on new Chinese stimulus measures contributed to this rise, with BHP, Rio Tinto, and Fortescue all recording notable gains.
Mineral Resources surged by 11.57 per cent, marking it as the day’s top performer.
Many mining stocks also witnessed substantial increases, including IGO and Pilbara Minerals.
In the energy sector, Woodside Energy and Ampol saw price increases amid renewed investor interest in riskier assets.
The big four banks notably supported the market’s advance, with Commonwealth Bank and ANZ both rising.
Meanwhile, local tech stocks showed mixed results as excitement grows with the US GTC conference beginning today.
The tech sector in Australia is anticipated to reach substantial growth in the coming years, as experts express cautious optimism amidst current market sentiment.
Dow gains over 650 points in relief bounce but still faces worst weekly loss since 2023 amid ongoing tariff uncertainties.
In Short
Stocks rebounded on Friday, with the Dow gaining 674.62 points, and the S&P 500 and Nasdaq experiencing their best day of 2025. Despite this, all major indices faced weekly losses due to ongoing trade policy concerns and declining consumer confidence.
Stocks rallied on Friday, reversing some losses from earlier in the week.
The Dow Jones Industrial Average gained 674.62 points, or 1.65%, closing at 41,488.19.
The S&P 500 climbed 2.13% to finish at 5,638.94, while the Nasdaq Composite rose 2.61% to settle at 17,754.09. This marked the best day for the S&P 500 and Nasdaq in 2025.
Big tech companies rebounded sharply, with Nvidia up over 5%, Tesla rising nearly 4%, and Meta Platforms gaining close to 3%.
Amazon and Apple also saw increases.
The market bounce was attributed to a lack of new tariff-related news from the White House, alleviating some investor concerns.
Following a drop on Thursday, the S&P 500 entered correction territory, having fallen more than 10% from its recent peak.
The Nasdaq slid deeper into correction, while the small-cap Russell 2000 neared a bear market. Uncertainty stemming from President Trump’s trade policies has contributed to heightened market volatility.
Despite Friday’s gains, the three major indices experienced weekly losses, with the Dow down about 3.1%—the worst week since March 2023. S&P 500 and Nasdaq both fell over 2% for their fourth straight weekly decline.
Consumer confidence also declined amid ongoing tariff concerns, with sentiment dropping to 57.9 in March.
Investors await an upcoming Federal Reserve policy meeting, where a majority expect interest rates to remain unchanged.
S&P 500 enters correction as stocks plummet amid Trump’s tariff threats, marking a challenging week for Wall Street.
In Short
Stocks plunged on Thursday, with the S&P 500 down 1.39% and entering correction territory, while the Dow and Nasdaq also fell significantly. Market uncertainty continues due to President Trump’s tariff threats, leading to losses predicted for the week across major indices.
Stocks fell sharply on Thursday as the S&P 500 entered correction territory, dropping 1.39% to close at 5,521.52.
The decline marked a significant downturn where the index sits 10.1% below its record high. The Dow Jones Industrial Average also suffered, losing 537.36 points or 1.3%, closing at 40,813.57, marking its fourth consecutive day of losses. Meanwhile, the Nasdaq Composite fell 1.96%, with major players like Tesla and Apple being negatively affected.
Tariff threat
The market’s downward trend has been exacerbated by recent tariff threats from President Trump. He proposed 200% tariffs on EU alcoholic products in response to a 50% EU tariff on whisky, indicating a firm stance on expanding trade restrictions.
Investor confidence has been shaken by his unpredictable trade policies, contributing to a week where the S&P 500 and Nasdaq are projected to post losses of 4.3% and 4.9%, respectively. The Dow is on track for a 4.7% decline, potentially experiencing its worst week since June 2022.
Small-cap stocks are also suffering, with the Russell 2000 nearing bear market conditions, down approximately 19% from its peak. Portfolio managers express concern that ongoing tariff disputes continue to foster market uncertainty.
Despite some positive signs in inflation data, analysts doubt a significant market rebound is likely, as worries about Trump’s trade approach remain a critical concern for investors.